Zai Lab Limited Is Well Positioned For Long-Term Growth
Zai Lab leverages partnerships and regulatory expertise to commercialize innovative drugs in China, reducing trial risks and accelerating market entry. A robust pipeline with multiple anticipated product launches each year, driving strong revenue growth toward a $1.5–$2 billion target by 2028. The company's strong balance sheet and diverse product portfolio minimize risk.
Zai Lab Limited (ZLAB) Q1 2025 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q1 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Jonathan Wang - Chief Business Officer Conference Call Participants Michael Yee - Jefferies Louise Chen - Scotiabank Yen-Der Li - Leerink Partners Li Watsek - Cantor Yigal Nochomovitz - Citi Anupam Rama - JPMorgan Jack Lin - Morgan Stanley Rebecca Liang - Bernstein Linhai Zhao - Goldman Sachs Operator Hello, ladies and gentlemen, thank you for standing by, and welcome to Zai Lab's First Quarter 2025 Financial Results Conference Call. At this time, all participants are in listen-only mode.
Zai Lab Limited (ZLAB) Reports Q1 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Zai Lab Limited (ZLAB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
All You Need to Know About Zai Lab Limited (ZLAB) Rating Upgrade to Buy
Zai Lab Limited (ZLAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zai Lab Limited (ZLAB) Moves 21.5% Higher: Will This Strength Last?
Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Zai Lab to Present New Data from Internally Developed, Next-Generation Oncology Candidates at AACR 2025 Annual Meeting
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company's internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunotherapy, will be presented during poster sessions at the upcoming American Association for Cancer Research.
Zai Lab: Innovative Pharma Set For Strong Year Of Business (And Share Price) Growth
Zai Lab Limited is an innovative Pharma partnering with US and European Pharmas to secure approvals for, and market their drugs in China. ZLAB stock has surged over 105% in the past year, driven by strong revenue growth and ambitious plans for future drug launches. The company aims to achieve $2bn in annual revenues by 2028, with key drugs like Vyvgart and Cobenfy leading the charge.
Zai Lab: Still Attractive Despite Higher Costs And Added Trade War Risks
ZLAB's Vyvgart revenue has been impressive, rising from roughly $93.6 million in 2024. I now consider this IP one of ZLAB's main growth drivers. ZLAB's ongoing strategy of focusing on Chinese approvals continues to pay off with Vyvgart Hytrulo, Xacduro, and Augtyro in oncology and autoimmune diseases. They also have late-stage assets like Bemarituzumab (gastric cancer), KarXT (schizophrenia), and Optune (pancreatic/lung cancer) that could become major revenue verticals in China.
Zai Lab Announces Acceptance of Biologics License Application for TIVDAK for the Treatment of Patients with Recurrent or Metastatic Cervical Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China's National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. “In China, cervical cancer is a serious health concern with approximately 150,000 new cases diagnosed annually1,”.
Wall Street Analysts Think Zai Lab Limited (ZLAB) Could Surge 64.42%: Read This Before Placing a Bet
The consensus price target hints at a 64.4% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zai Lab Announces Participation in Investor Conferences in March 2025
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company's senior management team will participate in the following investor conferences in March 2025: Leerink Partners 2025 Global Healthcare Conference Fireside Chat: Monday, March 10, 2025, 9:20 a.m. EST Location: Miami, FL Jefferies Biotech on the Beach Summit Time: Tuesday, March 11, 2025 Location: Miami, FL A live webcast of the fireside chat will be available on th.
Zai Lab Limited (ZLAB) Q4 2024 Earnings Call Transcript
Zai Lab Limited (NASDAQ:ZLAB ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Christine Chiou - Senior Vice President, Head of Investor Relations Samantha Du - Founder, Chairperson and Chief Executive Officer Josh Smiley - President and Chief Operating Officer Rafael Amado - President, Head of Global Research and Development Yajing Chen - Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Michael Yee - Jefferies Yen-Der Li - Leerink Partners Reena Patel - Citi Linhai Zhao - Goldman Sachs Li Wang Watsek - Cantor Fitzgerald Po Han Lin - Morgan Stanley Operator Hello, ladies and gentlemen. Thank you for standing by and welcome to Zai Lab's Fourth Quarter and Full Year 2024 Financial Results Conference Call.
